DAVENPORT & Co LLC Boosts Stake in Pfizer Inc. $PFE

DAVENPORT & Co LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 429,101 shares of the biopharmaceutical company’s stock after acquiring an additional 34,537 shares during the quarter. DAVENPORT & Co LLC’s holdings in Pfizer were worth $10,925,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer in the 1st quarter valued at approximately $27,000. Curio Wealth LLC increased its stake in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares during the last quarter. Bayforest Capital Ltd acquired a new stake in Pfizer in the first quarter valued at $28,000. Harbor Asset Planning Inc. bought a new position in Pfizer during the 2nd quarter valued at $29,000. Finally, Howard Hughes Medical Institute acquired a new position in Pfizer during the 2nd quarter worth $30,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.7%

Shares of NYSE PFE opened at $25.05 on Thursday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69. The company has a market cap of $142.40 billion, a price-to-earnings ratio of 14.56 and a beta of 0.46. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The stock’s 50 day simple moving average is $25.13 and its 200 day simple moving average is $24.88.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Key Stores Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Zacks highlights Pfizer’s strengthened oncology and obesity pipeline as potential drivers of post‑loss‑of‑exclusivity growth, which supports longer‑term revenue upside beyond 2026–2030 LOEs. PFE’s Oncology & Obesity Pipeline Position It for Post-LOE Growth
• Positive Sentiment: Reports that Pfizer is advancing biopharmaceutical operations globally point to improved manufacturing and commercial readiness, which can reduce execution risk for upcoming launches and support margins. Pfizer Inc (NYSE:PFE) Advances Biopharmaceutical Operations Globally
• Neutral Sentiment: Pfizer announced completion milestones in a pediatric Protonix (Phase 2) study — an incremental clinical update investors should watch for data readouts or regulatory next steps, but the item has limited immediate revenue impact until results are reported. Pfizer’s Protonix Pediatric Study Completion: What Investors Should Watch Next
• Negative Sentiment: Pfizer disclosed a patient death in a long‑term hemophilia study (linked to its Hympavzi/marstacimab program), prompting a safety review and reassessment of surgical protocols—this raises potential safety, regulatory and labeling risk that weighs on near‑term sentiment. Pfizer says patient dies after receiving hemophilia drug in trial
• Negative Sentiment: Management set FY‑2025 EPS guidance of $3.00–$3.15 and revenue guidance around $62.0B, both slightly below consensus — a near‑term earnings/revenue miss that increases uncertainty around 2025 results and likely contributed to selling pressure. (Market commentary tying the guidance cut and trial death to a tightened risk/reward is discussed here.) Did a Hympavzi Trial Death and Tighter Guidance Just Reframe Pfizer’s (PFE) Risk–Reward Story?

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. UBS Group reaffirmed a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Wolfe Research set a $24.00 price objective on Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. HSBC reiterated a “buy” rating and issued a $29.00 target price on shares of Pfizer in a research report on Wednesday, December 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $28.06.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.